



BHS AZPIRE AWARD

BHS, with the support of AstraZeneca, is pleased to announce a grant supporting a project aimed at improving patient support, well-being, and clinical outcomes during haematological cancer treatment.

Hematologists and paramedical professionals are invited to submit their project and apply for the AZpire Award

All information on rules and regulations (including the application form) are available on the BHS website.

The submission deadline is
Monday, 04 January 2027 (midnight CET).

The “AZpire Award” jury will select one winning project based on their innovative character, which will be awarded with EUR 20.000.

The winners will be personally informed before the 42nd BHS General Annual Meeting, March 12-13, 2027, during which they will be invited to present their winning project in English using a visual aid.

We are looking forward to receiving outstanding projects that can change the natural history of hematological diseases.



SCAN ME TO APPLY

AstraZeneca 

Sincerely,
Ann De Becker, President of the BHS



Award Criteria

Who can apply?

- Be a member of the BHS and a natural person.
- The project can be led by a paramedical professional practicing in a hospital setting (e.g. nurse, pharmacist, physiotherapist, social worker,...) but must be supervised by a hematologist.
- May not be an employee of the pharmaceutical industry.

Which projects are eligible?

- Clinical project focused on the optimisation of care for patients with blood disorders, both in hospital or outpatient setting (but with a link to the hospital).

Application requirements?

- You can apply online by **Monday, 04 January 2027** (midnight CET) via this link

<https://www.bhs.be/en/projects-and-grants/bhs-awards/azpire-award> or by scanning the QR code below.

Only online submissions will be considered.

Submissions sent by e-mail will not be considered.



Contact BHS Secretariat
Rue de la loi / Wetstraat 42,
1040 Brussels, Belgium
bhs@seauton-international.com
www.bhs.be



The AZpire Award has been made possible with an unrestricted grant from AstraZeneca

